Chemoinformaics analysis of (E)-oct-1-en-1-ol
| Molecular Weight | 128.215 | nRot | 5 |
| Heavy Atom Molecular Weight | 112.087 | nRig | 1 |
| Exact Molecular Weight | 128.12 | nRing | 0 |
| Solubility: LogS | -2.253 | nHRing | 0 |
| Solubility: LogP | 2.674 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 25 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 9 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 24.8307 |
| nHD | 1 | BPOL | 16.0513 |
| QED | 0.397 |
| Synth | 1.946 |
| Natural Product Likeliness | 1.541 |
| NR-PPAR-gamma | 0.109 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.011 |
| Pgp-sub | 0.002 |
| HIA | 0.003 |
| CACO-2 | -4.442 |
| MDCK | 0.0000208 |
| BBB | 0.994 |
| PPB | 0.378458 |
| VDSS | 1.617 |
| FU | 0.566276 |
| CYP1A2-inh | 0.741 |
| CYP1A2-sub | 0.712 |
| CYP2c19-inh | 0.175 |
| CYP2c19-sub | 0.481 |
| CYP2c9-inh | 0.103 |
| CYP2c9-sub | 0.809 |
| CYP2d6-inh | 0.038 |
| CYP2d6-sub | 0.284 |
| CYP3a4-inh | 0.038 |
| CYP3a4-sub | 0.115 |
| CL | 6.209 |
| T12 | 0.595 |
| hERG | 0.157 |
| Ames | 0.273 |
| ROA | 0.057 |
| SkinSen | 0.962 |
| Carcinogencity | 0.409 |
| EI | 0.986 |
| Respiratory | 0.964 |
| NR-Aromatase | 0.028 |
| Antiviral | No |
| Prediction | 0.955514 |